Simon T L, Akl B F, Murphy W
Ann Thorac Surg. 1984 May;37(5):359-64. doi: 10.1016/s0003-4975(10)60755-2.
Prophylactic administration of platelet concentrates to patients undergoing their first cardiopulmonary bypass operation (coronary artery bypass grafting or uncomplicated valve replacement) was evaluated in a controlled randomized study of 28 patients. Four units of platelet concentrates administered at the end of bypass prevented prolongation of the bleeding time seen in patients not receiving platelets. However, chest tube blood loss, transfusion requirements, and clinical outcome were not improved. Moreover, thrombocytopenia and prolongation of bleeding time did not correlate with blood loss or transfusion needs. Mild thrombocytopenia (to 58,000 platelets per microliter) and transient platelet dysfunction after bypass do not require administration of platelet concentrates, and prophylactic use of this blood component in the surgical setting of bypass is not indicated.
在一项针对28例患者的对照随机研究中，对首次接受心肺转流手术（冠状动脉搭桥术或单纯瓣膜置换术）的患者预防性输注血小板浓缩物进行了评估。在体外循环结束时输注4单位血小板浓缩物可防止未接受血小板输注的患者出现出血时间延长。然而，胸管失血量、输血需求及临床结局并未得到改善。此外，血小板减少症及出血时间延长与失血量或输血需求并无关联。体外循环后出现的轻度血小板减少症（降至每微升58,000个血小板）及短暂性血小板功能障碍并不需要输注血小板浓缩物，在体外循环手术中预防性使用这种血液成分并无必要。
